irak inhibitor6

IRAK inhibitor 6 is an inhibitor of interleukin-1 receptor-associated kinase 4 [IRAK-4, IC50: 160 nM].

PKA inhibitor fragment (6-22) amide Acetate is a synthetic peptide which selectively inhibits PKA activity by binding to its substrate site (IC50 < 2 nM).

CDK4/6/1 Inhibitor (Crozbaciclib) is a type of CDK4/6 inhibitor (IC50s: 3 and 1 nM). CDK4/6 inhibitor is a class of compounds used for the treatment of some types of hormone receptor positive, HER2-negative breast cancer, which can block the process of breast cancer cell division and reproduction.

Carbonic anhydrase inhibitor 6 is a potent human carbonic anhydrase (hCA) inhibitor that inhibits hCA IX, hCA II, hCA XII, and hCA I. It is used in the study of diseases caused by abnormalities in carbonic anhydrase.

IRAK inhibitor 2 (IRAK-IN-2) is a potent inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK-4) for the study of inflammation-related diseases.

Protein kinase inhibitor 6 (PKI 6) is a compound that acts as an inhibitor of protein kinases.

Tubulin inhibitor 6 (iHAP1) is an inhibitor of tubulin and a potent inhibitor of multiple cancer cell lines.

IK1 inhibitor PA-6 (PA-6) is a selective and potent inhibitor of IK1 (KIR2.x ion-channel-carried inward rectifier current) with an IC50 of 12-15 nM for human and mouse KIR2.x currents.

IRAK-4 protein kinase inhibitor 2 is a potent inhibitor of interleukin-1 receptor-associated kinase-4 (IC50 = 4 μM).

IRAK-1-4 Inhibitor I is a dual inhibitor targeting IRAK1 and IRAK4.

K-Ras(G12C) inhibitor 6 is an irreversible, allosteric inhibitor of the K-Ras(G12C) mutant, achieving 100% protein modification at 10 μM after 24 hours in vitro.

IRAK inhibitor 1 is an effective IRAK-4 inhibitor (IC50: 216 nM), is poorly active against JNK-1 (IC50: 3.801 μM) and JNK-2 (IC50>10 μM).

Thrombin Inhibitor 6, with an IC 50 of 1 nM, acts as a potent anticoagulant by inhibiting thrombin.

IRAK inhibitor 4 is a compound that functions as an inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). It specifically targets and inhibits the activity of IRAK4. The (trans) form of IRAK inhibitor 4 refers to its specific molecular configuration.

KRAS G12D inhibitor 6 is an efficacious compound that effectively inhibits KRAS G12D.

Topoisomerase I inhibitor 6 (Compound 3) is a potent Topoisomerase I inhibitor that traps the DNA-Top1 cleavage complex and exhibits low cytotoxicity in non-cancerous cell lines, making it valuable for research.

RIP1 Kinase Inhibitor 6 is a potent and selective inhibitor of RIP1 kinase, demonstrating inhibitory activity with an IC50 of less than 100 nM in a human R1P1 kinase assay[1].

Mcl-1 inhibitor 6 is a potent, orally active chemical compound that selectively inhibits the myeloid cell leukemia 1 (Mcl-1) protein, with a high affinity (K d = 0.23 nM) and binding activity (K i = 0.02 μM). This compound exhibits exceptional selectivity over other members of the Bcl-2 family, including Bcl-2, Bcl2A1, Bcl-xL, and Bcl-w (K d >10 μM). Notably, Mcl-1 inhibitor 6 demonstrates strong antitumor activity.

Glyoxalase I inhibitor 6 (Compound 9j) is an inhibitor of glyoxalase I (Glo-I) with an IC50 of 1.13 μM, exhibiting potential as a low-toxicity anticancer agent [1].

IRAK inhibitor 3 is a modulator of interleukin-1 (IL-1) receptor-associated kinase (IRAK).

SIRT5 Inhibitor 6 is a potent, selective, and substrate-competitive inhibitor of SIRT5 with an IC50 of 3.0 μM, demonstrating therapeutic potential for treating septic acute kidney injury (AKI) in vivo [1].

Chitin synthase inhibitor 6 (compound 9b) is a potent inhibitor of chitin synthase (CHS) with an IC50 of 0.21 mM, exhibiting broad-spectrum antifungal effects against drug-resistant fungi, and is useful for studying fungal infections.

GSK-3β inhibitor 6 is a highly potent inhibitor of GSK-3β with an IC50 value of 24.4 μM, significantly enhancing hepatocyte glucose uptake (38%). This compound holds great potential for studying diseases such as diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder [1].

ITK inhibitor 6 is a selective and potent ITK inhibitor that acts on ITK (IC50: 4 nM), BTK (IC50: 133 nM), JAK3 (IC50: 320 nM), EGFR (IC50: 2360 nM), LCK (IC50: 155 nM). ITK inhibitor 6 inhibited the phosphorylation of PLCγ1 and ERK1/2 and showed anti-proliferative effect.

FGFR1 inhibitor-6 is a potent FGFR1 inhibitor (IC50: 16.31 nM) with cytotoxic activity, capable of blocking the cell cycle in pro-G1 and G2 M phases, and inducing apoptosis.

Factor D inhibitor 6 is a potent, highly selective, and orally active compound that specifically inhibits the activity of factor D (FD) with an IC50 of 30 nM and a Kd of 6 nM. It does not exhibit inhibitory effects against factor B, classical and lectin complement-pathway activation, or a broad array of receptors, ion channels, kinases, and proteases.

Topoisomerase II inhibitor 6 (Compound 5), a tryptanthrin derivative, is a potent and selective topoisomerase II inhibitor that blocks the CCRF-CEM cell cycle in the G2 phase and induces DNA double-strand breaks (DSB). It exhibits antiproliferative activity on various tumor cell lines and has potential for cancer research [1].

Tuberculosis inhibitor 6 (compound 2c), a 3-methoxy-2-phenylimidazo[1,2-b]pyridazine derivative, is highly active against Mycobacterium tuberculosis (MIC 90 of ≤1.66 μM) and Mycobacterium marinum (MIC 90 of 2.65 μM) [1].

URAT1 inhibitor 6 (Compound 1h), with an IC50 of 35 nM for hURAT1, demonstrates 200-fold and 8-fold greater potency compared to Lesinurad and Benzbromarone, respectively. This compound is utilized in the study of inflammation [1].

PI3K mTOR Inhibitor-6 (Compound 19c) is a potent dual PI3K mTOR inhibitor, exhibiting greater stability than gedatolisib in artificial gastric fluid. At 10 μM, PI3K mTOR Inhibitor-6 significantly inhibits the PI3K Akt mTOR signaling pathway and has shown potential for cancer research.

HIV-1 inhibitor-6 (3-Pyridinecarboxamide, 1,4-dihydro-1-methyl-N-(5-nitro-1,2-benzisothiazol-3-yl)-4-oxo-) is a potent HIV-1 pre-mRNA selective splicing inhibitor that blocks HIV replication.

PKA Inhibitor Fragment (6-22) amide TFA (PKA Inhibitor Fragment (6-22) amide TFA) is a highly potent inhibitor of cAMP-dependent protein kinase A (PKA) with a Ki of 2.8 nM and reverses the pain-relieving effects of low levels of morphine in mice.

Microtubule inhibitor 6 (compound 17o) is a potent microtubule inhibitor exhibiting cytotoxicity against NCI-H460, BxPC-3, and HT-29 cells, with IC50 values of 14.0, 6.6, and 7.0 nM, respectively. It effectively inhibits microtubule polymerization.

IRAK inhibitor 4 is an inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4).

Compound 26F effectively optimizes enzyme inhibition (IC50 = 28.2 nM) while demonstrating relatively low cytotoxicity (IC50 = 3.32 μM). It induces apoptosis in MDA-MB-231 cells in a dose-dependent manner and efficiently arrests these cells in the G0/G1 phase.

KRAS inhibitor-6 is a potent inhibitor of the KRAS G12C variant.

PI3Kγ Inhibitor 6, a specific inhibitor of PI3Kγ, is utilized in the study of inflammatory and autoimmune diseases.

GLS1 Inhibitor-6 inhibitor ( IC 50 =68 nM), shows 220-fold selectivity for GLS2. GLS1 Inhibitor-6 shows good anti-tumor activity, antitumor cell proliferation activity and induces apoptosis .

ERK1 2 inhibitor 6 is a potent inhibitor of ERK1 2, showing potential for studying or preventing cancer, inflammation, and other proliferative diseases.

sEH inhibitor-6 (Compound 3g) is a highly potent soluble epoxide hydrolase (sEH) inhibitor, exhibiting an IC50 value of 0.5 nM [1].

α-Synuclein inhibitor 6 (compound 3ge) is a blood-brain barrier-permeable agent that effectively inhibits α-Synuclein (α-Syn) aggregation, demonstrating a potent IC50 value of 1.70 μM and achieving an inhibition ratio of 94.4% at 30 μM [1].